1,721,322 research outputs found
ESMO Open special series on new emerging targets in cancer immunotherapy
No full textClick here to listen to the Podcast
ESMO Open: News in breast cancer 2019
No full textClick here to listen to the Podcast https://doi.org/10.1136/esmoopen-2020-00079
ESMO20 YO for YO: highlights on new drugs in advanced breast cancer focusing on sacituzumab govitecan and alpelisib
No full textsponsorship: Pfizer, AstraZeneca, Novartis, Eli Lilly and Company, F. Hoffmann-La Roche, Teva Pharmaceutical Industries, Vifor Pharmastatus: Publishe
Temporary Ovarian Suppression With Gonadotropin-Releasing Hormone Agonist During Chemotherapy for Fertility Preservation: Toward the End of the Debate?
No full textTemporary ovarian suppression with gonadotropin‐releasing hormone agonist during chemotherapy might be a reliable strategy not only to preserve ovarian function but also to increase the likelihood of becoming pregnant after the end of cytotoxic therapy. The findings of Blumenfeld et al. are consistent with recent data suggesting the efficacy of this strategy in preserving fertility
ESMO20 YO for YO: highlights on adjuvant CDK4/6 inhibitors in early hormone receptor-positive/HER2-negative breast cancer
No full textOncofertility and covid-19—cancer does not wait
No full textThe current pandemic due to the coronavirus disease 2019 (COVID-19) outbreak has forced physicians to review their current clinical practice and guidelines. Although elective procedures using assisted reproductive technologies (ART) should be preferably canceled or postponed at this time, this does not always apply to urgent procedures such as those in patients with cancer. A complete oncofertility counseling balancing the benefits and risks of undergoing fertility preservation before commencing gonadotoxic therapies (chemotherapy and/or radiotherapy) should also be provided during the COVID-19 outbreak. This article briefly highlights what patients, oncologists and fertility specialists need to keep in mind during oncofertility counseling at the time of the COVID-19 outbreak
Corrigendum to ‘Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review’: [ESMO Open Volume 6, Issue 5, October 2021, 100276] (ESMO Open (2021) 6(5), (S2059702921002386), (10.1016/j.esmoop.2021.100276))
No full textThe authors regret that the affiliations for Professor F. Puglisi are incorrect. They should be: CRO Aviano National Cancer Institute IRCCS, Aviano, Italy and Department of Medicine (DAME), University of Udine, Udine, Italy The authors would like to apologise for any inconvenience caused
Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review
No full textImmune checkpoint inhibitors (i.e. anti-PD1, anti-PDL1, and anti-CTLA4) have revolutionized the therapeutic approach of several cancer types. In a subset of metastatic patients, the duration of the response is so long that a cure might be hypothesized, and a treatment discontinuation strategy could be proposed. Considering that long-term efficacy, some patients could also plan to have a child. Moreover, immunotherapy is moving to the early setting in several diseases including melanoma and breast cancer that are common cancers in young patients. However, there is a paucity of data about their potential detrimental effect on fertility, pregnancy, or sexuality. Herein, we conducted a systematic review with the aim to comprehensively collect the available evidence about fertility, pregnancy, and sexual adverse effects of checkpoint inhibitors in order to help clinicians in daily practice and trialists to develop future studies
- …
